Literature DB >> 1936616

Endoneurial microvessels in human diabetic neuropathy. Endothelial cell dysjunction and lack of treatment effect by aldose reductase inhibitor.

A A Sima1, V Nathaniel, A Prashar, V Bril, D A Greene.   

Abstract

Endoneurial microvascular abnormalities have been invoked in the pathogenesis of diabetic distal symmetric polyneuropathy. Detailed morphometric analysis of the endoneurial microvasculature was correlated with previously published data on nerve fiber morphometry and teased fiber analysis obtained from the same sural nerve biopsies. Biopsy specimens from neuropathic diabetic patients were obtained before and after 12 mo of aldose reductase inhibitor (ARI) treatment and compared to 15 carefully age-matched control subjects. Diabetic microvessels showed basement membrane thickening and loss of endothelial cell tight junctions. Microvascular density and the frequency of microvessels closed by endothelial cells increased with age in diabetic and control nerves and were unaffected by diabetes. The density of microvessels showing patent lumina did not differ between control and diabetic subjects and was not related to age or diabetes. Closed microvessels were composed of postcapillary venules that were otherwise devoid of ultrastructural abnormalities. We suggest that microvascular closure by endothelial cells may be a physiological condition and is unlikely to have any pathogenetic significance in diabetic neuropathy. Based on the current limited biopsy material, we conclude that 12 mo of ARI treatment that induced significant fiber repair and regeneration had no detectable effect on endoneurial microvascular abnormalities. These data suggest that endoneurial vascular pathology is not a rate-limiting factor in fiber damage or repair at this stage of diabetic neuropathy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1936616     DOI: 10.2337/diab.40.9.1090

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  8 in total

Review 1.  Emerging therapy for diabetic neuropathy: cell therapy targeting vessels and nerves.

Authors:  Hyongbum Kim; Julie J Kim; Young-sup Yoon
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2012-06       Impact factor: 2.895

2.  Endoneurial microvascular pathology in feline diabetic neuropathy.

Authors:  Jeannelyn S Estrella; Richard N Nelson; B K Sturges; Karen M Vernau; D Collette Williams; Richard A LeCouteur; G Diane Shelton; Andrew P Mizisin
Journal:  Microvasc Res       Date:  2007-12-23       Impact factor: 3.514

Review 3.  The efficacy of aldose reductase inhibitors in the management of diabetic complications. Comparison with intensive insulin treatment and pancreatic transplantation.

Authors:  J M van Gerven; A M Tjon-A-Tsien
Journal:  Drugs Aging       Date:  1995-01       Impact factor: 3.923

Review 4.  Diabetic neuropathy in the elderly.

Authors:  A A Sima; D A Greene
Journal:  Drugs Aging       Date:  1995-02       Impact factor: 3.923

5.  Endoneurial localisation of microvascular damage in human diabetic neuropathy.

Authors:  R A Malik; S Tesfaye; S D Thompson; A Veves; A K Sharma; A J Boulton; J D Ward
Journal:  Diabetologia       Date:  1993-05       Impact factor: 10.122

6.  Long-term suppression of postprandial hyperglycaemia with acarbose retards the development of neuropathies in the BB/W-rat.

Authors:  A A Sima; S Chakrabarti
Journal:  Diabetologia       Date:  1992-04       Impact factor: 10.122

Review 7.  Diabetic neuropathy in elderly patients. What can be done?

Authors:  J Belmin; P Valensi
Journal:  Drugs Aging       Date:  1996-06       Impact factor: 3.923

Review 8.  Mechanism of diabetic neuropathy: Where are we now and where to go?

Authors:  Soroku Yagihashi; Hiroki Mizukami; Kazuhiro Sugimoto
Journal:  J Diabetes Investig       Date:  2011-01-24       Impact factor: 4.232

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.